目的 采用快速卫生技术评估(HTA)方法评价奥拉帕利治疗晚期卵巢癌患者的安全性、有效性和经济性,为其临床合理用药提供循证参考。方法 系统检索中英文数据库,由两位研究者分别依照纳入和排除标准对文献进行独立筛选、数据提取,评价文献质量,最终采用定性描述的方法对结果进行汇总分析。结果 共纳入Meta分析7篇,经济学研究9篇。结果显示,与常规化疗比较,奥拉帕利治疗晚期卵巢癌患者的不良反应发生率降低;与安慰剂比较,会出现一些轻度或中度不良反应,但易于控制。相较于安慰剂和常规化疗,奥拉帕利可延长患者无进展生存期(PFS);值得注意的是,乳腺癌易感基因(BRCA),阳性的患者临床获益更多。纳入的经济学研究均未显示出奥拉帕利的优势。结论 奥拉帕利治疗晚期卵巢癌患者具有良好的安全性和有效性,未来有必要在国内开展其药物经济学研究。
Abstract
OBJECTIVE To evaluate the safety, efficacy and economics of olaparib in the treatment of patients with advanced ovarian cancer using rapid health technology assessment and provide evidence-based support for its clinical drug use. METHODS Relevant Chinese and English databases were searched systematically. Two researchers independently screened the literature, extracted the data, evaluated the quality and performed a comprehensive analysis according to the inclusion and exclusion criteria, and finally the results were summarized and analyzed by the method of qualitative description. RESULTS A total of 7 systematic reviews/Meta analyses and 9 pharmacoeconomic studies were included. The results showed that compared with conventional chemotherapy, olaparib had a lower incidence of adverse reactions in patients with advanced ovarian cancer. Compared with placebo, there were some mild or moderate adverse reactions, but they were easy to control. Olaparib could prolong PFS in patients compared with placebo and conventional chemotherapy, and it is worth noting that BRCA-positive patients have more clinical benefits. None of the included pharmacoeconomic studies showed olaparib advantages. CONCLUSION Olaparib has good safety and efficacy in the treatment of platinum-sensitive recurrent ovarian cancer. In the future, it is necessary to carry out its pharmacoeconomic research in China.
关键词
奥拉帕利 /
卵巢癌 /
快速卫生技术评估
{{custom_keyword}} /
Key words
olaparib /
ovarian cancer /
rapid health technology assessment
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2] TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(4):284-296.
[3] TANG H L, MEN P, ZHAI S D. Introducing and exploring the method of rapid review on drugs [J]. Clin Med J,2016, 14(2):1-4.
[4] WANG Z H, LI T, ZHAO Z N, et al. A rapid health technology assessment of nimotuzumab applicated in patients with advanced nasopharyngeal carcinoma [J]. Chin Pharm J(中国药学杂志), 2021, 56(1): 75-80.
[5] LI T, ZHAO Z N, HU X, et al. Ilaprazole enteric-coated tablets in the treatment of duodenal ulcer: a rapid health technology assessment [J]. Chin Pharm J(中国药学杂志), 2020, 55(13): 1111-1116.
[6] SHEA B J, GRIMSHAW J M, WELLS G A, et al. Bouter LM.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews[J]. BMC Med Res Methodol, 2007, 7(10):1-7.
[7] HUSEREAU D, DRUMMOND M, PETROU S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement[J]. Int J Technol Assess Health Care, 2013, 14(3): 367-372.
[8] FU H. A meta-analysis of the efficacy and safety of Olaparib in the treatment of ovarian cancer [D]. Yanan:Yanan University, 2020.
[9] RICCI A D, RIZZO A, NOVELLI M, et al. Specific toxicity of maintenance olaparib versus placebo in advanced malignancies: a systematic review and meta-analysis [J]. Anticancer Res, 2020, 40(2): 597-608.
[10] MA J, DENG H, LI J, et al. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials[J]. Cancer Manag Res, 2019, 11(4): 3061-3078.
[11] GUO X X, WU H L, SHI H Y, et al. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials [J]. Cancer Manag Res, 2018, 10(10): 2553-2562.
[12] WIGGANS A J, CASS G K, BRYANT A, et al. Poly(ADP-ribose) polymerase(PARP) inhibitors for the treatment of ovarian cancer[J]. Cochrane Database Syst Rev, 2015, 2015(5):CD007929.
[13] BAO Z, CAO C, GENG X, et al. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis [J]. Oncotarget, 2016, 7(7): 7629-7639.
[14] LIANG J H, LUO R L. Therapeutic effects and safety of olaparib on treatment of recurrent serosity ovarian cancer: a meta-analysis [J]. J Hubei Univ Med(湖北医药学院学报), 2015, 34(6): 538-542,547.
[15] MOYA A C, GONZALEZ D A, IVANOVA M Y, et al. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? [J]. Gynecol Oncol, 2022, 164(2):406-414.
[16] LEUNG J H, LANG H C, WANG S Y, et al. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer[J]. Expert Rev Pharmacoecon Outcomes Res, 2022, 22(3):489-496.
[17] CHENG L J, WONG G, CHAY W Y, et al. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer[J]. Expert Rev Pharmacoecon Outcomes Res, 2021, 21(3):441-448.
[18] TAN D S, CHAN J J, HETTLE R, et al. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore [J]. J Gynecol Oncol, 2021, 32(2): 27-35.
[19] WU L, ZHONG L. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US [J]. J Med Econ, 2019, 22(2):187-195.
[20] ZHONG L, TRAN A T, TOMASINO T, et al. Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer [J]. J Manag Care Spec Pharm, 2018, 24(12): 1219-1228.
[21] DELGADO O L, GINES R J, GARCIAS D E, et al. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain [J]. Farm Hosp, 2018, 42(3): 95-102.
[22] SMITH H J, WALTERS H CL, AREND R C, et al. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer:a cost-effectiveness analysis [J]. Gynecol Oncol, 2015, 139(1):59-62.
[23] SECORD A A, BARNETT J C, LEDERMANN J A, et al. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer [J]. Int J Gynecol Cancer, 2013, 23(5): 846-852.
[24] WU X, WU L, KONG B, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients [J]. Int J Gynecol Cancer, 2017, 27(8): 1650-1657.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
苏州市科技发展计划(民生科技-医疗卫生应用基础研究)项目资助(SYSD2020180,SYSD2020181)
{{custom_fund}}
PDF(1133 KB)
